TrialEBioMedicine2015

TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients.

Daniela Kandioler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.